2630Vigonvita Life Sciences Co., Ltd.

🇭🇰 Hong Kong Borsası
76.55
HKD
Analysis Scores
Lothien Robustness Score?
16/100
Very Weak
Neden bu skor?
Damodaran ?
0/100
DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
53/100
Piotroski ?
N/A
Yetersiz çeyrek verisi: 4 mevcut, en az 5 gerekli
Graham ?
Negatif HBK
Company is loss-making (EPS = -2.4948 TL) — Graham formula requires positive earnings
Active Metric?
1/4
Confidence?
43%
Lothien Robustness Summary
27/100
Lothien Sağlamlık: Çok Zayıf (27/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 0 | Negatif: 3 | Nötr: 2
Net Zarar
Son çeyrekte -HK$105M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Yüksek PD/DD
PD/DD: 24.58. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Negatif ROE
ROE: %-79.7. Şirket özsermayesini eritiyor.
Lothien Sağlamlık Skoru: 16/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı zayıf görünüyor.

Data date 2026-10-22 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-22
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
235 days
Annual Volatility ?
%90.7
VaR 95% ?
%9.27
daily max loss
VaR 99% ?
%13.16
daily max loss
CVaR 95% ?
%13.49
expected loss (tail)
Max Drawdown ?
%60.2
24.02.2026 → 20.07.2026
Skewness ?
0.23
Parametrik%9.27
Historik%7.76
Cornish-Fisher%8.34
Return Distribution
Valuation
Potential?
-32.2%
ROIC ?
-34.5%
Debt Cycle?
Contraction
Balance Sheet Analysis? Q2025/12
Net kâr çeyreklik yatay seyrede (-104.5M HKD, %+0.0)
Hasılat çeyreklik yatay kaldı (30.0M HKD)
Brüt kâr marjı güçlü: %79.0
Net kâr marjı negatif: %-348.4 — zarar ediyor
FAVÖK yatay seyrede (-89.5M HKD)
FAVÖK marjı düşük: %-298.3
Toplam borç: 760.0M HKD
Net borç hasılatın üzerinde: 233.4M HKD
Borç/Özkaynak oranı: 1.45x
Cari oran: 1.07x — yeterli likidite
Nakit ve benzerleri: 526.6M HKD
İşletme nakit akışı negatif: -28.4M HKD
Serbest nakit akışı negatif: -76.5M HKD — yatırımlar nakdi aşıyor
ROE negatif: %-19.9 — zarar var
ROA düşük: %-6.9
Toplam varlıklar: 1.5B HKD (%+0.0)
Özkaynak: 524.5M HKD (%+0.0)
İşletme kârı negatif: -92.6M HKD — faaliyet zararı
Faiz gideri: 5.7M HKD
Ödenmiş sermaye: 167.6M HKD
Net işletme sermayesi pozitif: 43.6M HKD
Yoğun yatırım dönemi: CAPEX/Hasılat %160.4 (48.1M HKD)
Son 4 çeyrek ardışık zarar
Fiyat TRAMA-99 altında: %-8.2 — teknik trend olumsuz
Direnç seviyesi: TRAMA-99 = 83.43 HKD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %-348.4
Net profit margin %-348.4 — loss period. Compared to previous quarter +0.0 point increase.
ROE - Return on Equity (TTM) %-79.7
ROE %-79.7 — negative return on equity.
EBITDA Margin %-298.3
EBITDA margin %-298.3 — operational loss.
Gross Profit Margin %79.0
Gross profit per revenue %79.0. Strong pricing power.
Free Cash Flow Margin (TTM) %-255.1
TTM Free Cash Flow is %-255.1'i. Negative FCF — company consuming cash.
Valuation
P/B Ratio 24.58x Sector: 2.37x
PD/DD 24.58x — sector median's %937 above. Expensive book value.
Indebtedness
Current Ratio 1.07x
Current ratio 1.07x — borderline, attention required.
Debt / Equity 1.45x
Debt/Equity 1.45x — moderate financial leverage.
Interest Coverage -15.7x
Interest coverage -15.7x — critical level. Risk of difficulty in interest payments.
Growth
No balance sheet data
Score Explanations
Lothien Robustness
16/100
Very weak robustness (16/100). Multiple critical indicators are red: high debt, low profitability or excessive valuation.
Very Weak
Potential
-32.2%
Minus %32.2 expected value (52.34) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %43.
Components: P/B target: 19.31
Damodaran Valuation
0/100
Very Weak
Dalio Risk Analysis
53/100
Moderate debt risk (53/100). Interest coverage ratio -15.7x — weak, fragile.
Leverage: 28/100 | Debt Service: 54/100 | Quality: 25/100
ROIC - Return on Capital
%-34.5
ROIC (%-34.5) cost of capital (10.1%) below → destroying value.
WACC: %10.1
Debt Cycle Phase
Contraction
High debt service + falling revenues. Balance sheet under pressure.
Piotroski F-Score
—
Graham Intrinsic Value
—
Company is loss-making (EPS = -2.4948 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
24.58x vs 2.37x
Compared to sector %937 more expensive (by book value)
ROIC vs WACC
%-34.5 vs %10.1 WACC
ROIC 44.6 bps below cost of capital
TRAMA-99 Trend — Downtrend
Price (76.55), TRAMA-99 line's %8.2 below. Downtrend ongoing — technical outlook negative. Pressure may continue until TRAMA is broken above.
Price:: 76.55
TRAMA: 83.43
Difference: %-8.2
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
2630 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.